Resolutions at the Annual General Meeting in Biotage AB on April 29, 2008

Resolutions at the Annual General Meeting in Biotage AB on April 29, 2008

At the Annual General Meeting held in Biotage AB (Reg. No. 556539-3138) on April
29, 2008, the following resolutions were passed, among others.

Appropriation of the company's result
The General Meeting resolved that the company's accumulated losses amounting to
667,6 MSEK shall be covered by reducing the statutory reserve with the
equivalent amount.

Board of Directors etc.
The General Meeting resolved to re-elect Ove Mattsson, Thomas Eklund, Annika
Espander, Staffan Lindstrand, Anders Rydin, Bengt Samuelsson, Axel Broms,
Per-Olof Eriksson and Mathias Uhlén as Board members. The General Meeting
resolved to appoint Ove Mattsson Chairman of the Board. 

The General Meeting resolved that a fee of SEK 1,400,000 shall be paid to the
Board of Directors for the period up to and including the Annual General Meeting
2008 to be distributed as follows: the Chairman shall receive SEK 400,000 and
each of the other Board members elected by the General Meeting who are not
employed by the company shall receive SEK 125,000. In addition to that, a fee
shall be paid to the members of the Auditing Committee of an aggregate of not
more than SEK 100,000, whereof the Chairman shall receive SEK 50,000 and the
other members SEK 25,000 each.

At the General Meeting it was informed that the employee organisation
“Civilingenjörsförbundet” and “Naturvetarna” at Biotage have appointed
Per-Gunnar Eriksson to employee Board representative, and that the employee
organisation “Unionen” at Biotage has appointed Maritha Lundin to alternate
Board representative. 

Auditors
The General Meeting resolved to elect Deloitte AB, with Marcus Sörlander as
auditor in charge, as the company's auditor for the period until the end of the
General Meeting held 2012.

Nomination Committee
The General Meeting resolved that the Chairman of the Board of Directors shall
be appointed as member of the Nomination Committee and shall be instructed to
appoint, in consultation with the (by voting rights) major shareholders of the
company as per September 1, 2008, another three members. The names of such
members shall be published no later than six months before the Annual General
Meeting 2009. The Nomination Committee shall appoint one of the members to be
the Chairman of the Committee. The Chairman of the Board may not be appointed
Chairman of the Nomination Committee.

The Nomination Committee shall, before the Annual General Meeting 2009, prepare
proposals for the election of Chairman and other members of the Board of
Directors, the election of Chairman of the Annual General Meeting, the
determination of fees and matters pertaining thereto.

Resolution on guidelines for compensation for the executive management
The General Meeting resolved to adopt guidelines for compensation for the
executive management in accordance with the proposal by the Board of Directors.

Authorization for the Board of Directors to issue shares and/or convertibles
The General Meeting resolved to authorize the Board to issue shares and/or
convertibles with or without deviation from the shareholders' pre-emption
rights. The Board of Directors shall have the right to resolve that the shares
and/or the convertibles shall be paid in kind or otherwise be subject to
conditions referred to in Chapter 2 Section 5 second paragraph 1-3 and 5 of the
Swedish Companies Act or that the shares and/or the convertibles shall be
subscribed for with a right of set-off. The Board's resolutions may result in an
increase of the number of shares in the company by not more than 8,800,000
shares in total. 

Uppsala, April 29, 2007
Biotage AB (publ)
The Board of Directors

Contact:
Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84, torben.jorgensen@eu.biotage.com

About Biotage 
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market.
The company offers solutions, knowledge and experience in the areas of genetic
analysis and medicinal chemistry. In 2005 operations and products were acquired
from the American company Argonaut, further strengthening the medicinal
chemistry product range. The customers include the worlds top 30 pharmaceutical
companies, the worlds top 20 biotech companies, and leading academic institutes.
The company is headquartered in Uppsala and has offices in the U.S., Japan, UK,
Germany and several other European countries. Biotage has 336 employees and had
sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange
Stockholm AB. Website: www.biotage.com